Back to the full story14 sources · FDA approves breakthrough pancreatic cancer treatment◆ Analytics
FDA approves breakthrough pancreatic cancer treatment
Deterministic text analytics computed across all 14 sources. Frequency, entity overlap, and claim overlap — computed counts only. Nothing is rated true or false.
01
Frequency Analytics
The most common words and exact phrases across every report in this cluster. Computed counts only.
Top words
cancerpancreaticdrugapprovespatientsdaraxonrasibtreatmentpillapprovedrasonque
Top phrases
pancreatic cancerfda approvespancreatic cancer drugcancer drugfirst of kindkind pill called daraxonrasibadvanced pancreatic cancerfirst of kind pill calledpill called daraxonrasibapproves breakthrough
02
Entity Overlap
Names detected in the report text: which appear across multiple sources, and which only one source mentions.
Across multiple sources
- FDA · 10 sources
- Patients · 5 sources
- Rasonque · 5 sources
- Drug Administration · 4 sources
- Pancreatic · 4 sources
- Revolution Medicines · 4 sources
- Ben Sasse · 3 sources
- The Food · 3 sources
- U.S · 3 sources
- California · 2 sources
- CBS · 2 sources
- Neb · 2 sources
Unique to one source
- Doctor · CBS News — Top
- FDA'a · CBS News — Top
- CBS News · CBS News — Top
- The US FDA · France 24
- Boston · WCVB
- Experts · BBC News
- Food · Fox News
- Today’s · Fox News
- FDA Commissioner Kyle Diamantas · Fox News
- Omaha · WOWT
- WASHINGTON · Chicago Sun-Times
- It's · Chicago Sun-Times
03
Claim Overlap
Near-identical sentences found in two or more reports, versus sentences that appear in only one. Text match only — nothing is rated true or false.
Repeated across sources
- "The drug garnered public attention earlier this year when former Sen." · 2 sources
- "patients a more effective treatment against one of the deadliest types of cancer." · 2 sources
- "The daily pills will be sold by Revolution Medicines under the brand name Rasonque." · 2 sources
- "What are known as KRAS mutations are especially critical in fueling pancreatic cancer." · 2 sources
- "The new drug targets mutations in the RAS gene family that normally regulates cell growth." · 2 sources
- "Ben Sasse , R-Neb., described on CBS' “60 Minutes” how he has had less pain while taking it." · 2 sources
- "FDA regulators noted on Wednesday that they approved the drug more than six months ahead of their target date." · 2 sources
- "Patients getting the new treatment lived for a median of 13.2 months compared with 6.7 months for chemotherapy recipients." · 2 sources
Appears once
- "Patients taking the first-of-a-kind pill, called daraxonrasib, lived for a median of 13.2 months compared with 6.7 months for chemotherapy recipients, studies showed." · CBS News — Top
- "The FDA has approved a drug that could extend the life of patients with late-stage pancreatic cancer." · CBS News — Top
- "The US FDA on Wednesday approved Revolution Medicines' Rasonque for advanced pancreatic cancer, opening a new treatment option for patients with metastatic disease." · France 24
- "A large trial found the once-daily pill doubled survival rates, offering fresh hope for people who have exhausted other treatments." · France 24
- "Experts have hailed the drug, daraxonrasib, as a game changer for one of the world's deadliest cancers." · BBC News
- "Revolution Medicines' Rasonque targets the RAS protein driving 95% of pancreatic adenocarcinoma cases, offering a critical option after chemotherapy fails." · Fox News
- "Food and Drug Administration approved the use of a new cancer treatment pill Wednesday." · Fox News
- "In a large-scale clinical trial, people taking daraxonrasib lived twice as long as those given standard chemotherapy." · Gizmodo